Evidence map›Paper›PMID 40434671›Full record

ArticleCurrent medical science2025

FOXM1 Promotes Non-Small Cell Lung Cancer Progression by Increasing CHEK1 Expression.

Xiao-Ning Lu, Jun Chen, Guang Han, Cheng Ding, Chang Li, Chun Xu, Yuan Cui, Sheng Ju, Xin Tong, Jun Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao-Ning Lu *Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jun Chen *Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Guang Han *Department of Respiratory Medicine, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, 223800, China.
Cheng DingDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Chang LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Chun XuDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yuan CuiDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Sheng JuDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Xin TongDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. txin@suda.edu.cn.
Jun ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. zhaojia0327@126.com.ORCID http://orcid.org/0000-0001-8903-8205

Funding

The present study was funded by the Suqian Science and Technology Program Project K202008
6 · The paper itself

Abstract

objectiveNon-small cell lung cancer (NSCLC) is a leading cause of cancer-associated mortality. This study aimed to investigate the role of checkpoint kinase 1 (CHEK1) in NSCLC progression and its regulatory relationship with forkhead box protein M1 (FOXM1).

methodsTranswell assays were used to evaluate the migration and invasion capabilities of NSCLC cells with either CHEK1 overexpression or knockdown. The expression of epithelial-mesenchymal transition (EMT) markers in NSCLC cells under CHEK1 overexpression or knockdown conditions was analyzed via Western blotting. Proliferative capacity was assessed using CCK-8 assays in NSCLC cells with modulated CHEK1 expression. Additionally, real-time quantitative PCR was employed to measure CHEK1 and FOXM1 expression levels in NSCLC tissues. The effects of CHEK1 knockdown on tumor growth were further validated in animal models. The binding of FOXM1 to the CHEK1 promoter region was examined using dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP) assays.

resultsFOXM1 and CHEK1 were upregulated in NSCLC tissues. CHEK1 overexpression promoted NSCLC cell proliferation, while its knockdown suppressed proliferation, inhibited EMT, and reduced tumor growth in vivo. FOXM1 was shown to directly bind to CHEK1 promoter, thereby upregulating CHEK1 expression.

conclusionCHEK1 promotes NSCLC cell proliferation and tumor growth, and its expression is regulated by FOXM1. These findings suggest CHEK1 and FOXM1 are potential therapeutic targets for NSCLC treatment.

Indexed as

Carcinoma, Non-Small-Cell LungCheckpoint Kinase 1Forkhead Box Protein M1Lung NeoplasmsA549 CellsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceCheckpoint Kinase 1CHEK1 protein, humanForkhead Box Protein M1FOXM1 protein, humanCheckpoint kinase 1Forkhead box protein M1Non-small cell lung cancerTherapeutic targetsTranscriptional activation

Identifiers

PMID40434671

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.